Bradley William Caprathe
Pfizer
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Bradley William Caprathe.
Bioorganic & Medicinal Chemistry Letters | 2009
Lloyd Jerome Simons; Bradley William Caprathe; Michael J. Callahan; James Michael Graham; Takenori Kimura; Yingjie Lai; Harry LeVine; William J. Lipinski; Annette Theresa Sakkab; Yoshikazu Tasaki; Lary C. Walker; Tomoyuki Yasunaga; Yuyang Ye; Nian Zhuang; Corinne E. Augelli-Szafran
It is believed that beta-amyloid aggregation is an important event in the development of Alzheimers disease. In the course of our studies to identify beta-amyloid aggregation inhibitors, a series of N-phenyl anthranilic acid analogs were synthesized and studied for beta-amyloid inhibition activity. The synthesis, structure-activity relationship, and in vivo activity of these analogs are discussed.
Bioorganic & Medicinal Chemistry Letters | 2010
Paul Galatsis; Bradley William Caprathe; John Gilmore; Anthony Thomas; Kristin Linn; Susan M. Sheehan; William Glen Harter; Catherine Rose Kostlan; Elizabeth A. Lunney; Charles Stankovic; John Rubin; Kenneth Dale Brady; Hamish Allen; Robert V. Talanian
Succinic acid amides have been found to be effective P2-P3 scaffold replacements for peptidic ICE inhibitors. Heteroarylalkyl fragments occupying the P4 position provided access to compounds with nM affinities. Utilization of an acylal prodrug moiety was required to overcome biopharmaceutical issues which led to the identification of 17f, a potential clinical candidate.
Bioorganic & Medicinal Chemistry Letters | 2010
Paul Galatsis; Bradley William Caprathe; Dennis M. Downing; John Gilmore; William Glen Harter; Sheryl Hays; Catherine Rose Kostlan; Kristin Linn; Elizabeth A. Lunney; Kim Para; Anthony Thomas; Joseph Scott Warmus; Hamish Allen; Kenneth Dale Brady; Robert V. Talanian; Nigel Walker
A series of acyloxyalkyl and amidooxyalkyl ketones appended to a carbobenzyloxy aspartic acid core have been prepared. The most potent of these new inhibitors was 4i with a K(i) of 0.5 microM. These two series provide an improved understanding of the binding requirements for the hydrophobic prime side of ICE.
Journal of Medicinal Chemistry | 1998
Sheryl Jeanne Hays; Bradley William Caprathe; John L. Gilmore; Nilam Amin; Mark R. Emmerling; Walter Michael; Ravi Nadimpalli; Rathna Nath; Kadee J. Raser; Daniel Stafford; Desiree Watson; Kevin K. W. Wang; Juan C. Jaen
Archive | 1997
Bradley William Caprathe; John L. Gilmore; Sheryl Jeanne Hays; Juan C. Jaen; Harry LeVine
Archive | 1993
Juan C. Jaen; Bradley William Caprathe
Archive | 1997
Hans-Peter Albrecht; Hamish Allen; Kenneth Dale Brady; Bradley William Caprathe; John L. Gilmore; William Glen Harter; Sheryl J. Hays; Catherine Rose Kostlan; Elizabeth A. Lunney; Kimberly Suzanne Para; Anthony Jerome Thomas; Nigel Walker
Bioorganic & Medicinal Chemistry Letters | 2004
William Glen Harter; Hans Albrect; Kenneth Dale Brady; Bradley William Caprathe; James B. Dunbar; John Gilmore; Sheryl Hays; Catherine Rose Kostlan; Beth Lunney; Nigel Walker
Archive | 1990
Bradley William Caprathe; Juan C. Jaen; Sarah Jane Smith; Lawrence D. Wise
Archive | 2004
Bradley William Caprathe; Shelly Ann Glase; Zissis Konstantinou; Robert Michael Schelkun; Susan M. Sheehan; Anthony Jerome Thomas; Po-Wai Yuen